Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Repsold, Lisa![]() |
|
dc.contributor.author | Pool, Roger![]() |
|
dc.contributor.author | Karodia, Mohammed![]() |
|
dc.contributor.author | Tintinger, Gregory Ronald![]() |
|
dc.contributor.author | Becker, Piet J.![]() |
|
dc.contributor.author | Joubert, Anna Margaretha![]() |
|
dc.date.accessioned | 2022-03-30T06:19:25Z | |
dc.date.available | 2022-03-30T06:19:25Z | |
dc.date.issued | 2021-06 | |
dc.description.abstract | Chronic myeloid leukaemia (CML) is a malignancy of the haematopoietic stem cells. The first line of treatment for CML, especially in developing countries, remains the first-generation tyrosine kinase inhibitor, Imatinib. Patients with CML are frequently diagnosed with platelet abnormalities. However, the specific mechanism of platelet abnormalities in CML remains unclear and poorly understood. The aim of this study was therefore to determine the apoptotic profiles of CML patients ex vivo on platelets before and after treatment with Imatinib. Blood samples of healthy volunteers and CML patients at diagnosis and after 6 months treatment with Imatinib were collected. Platelet counts, viability and activation were determined. Results showed that CML patients' platelet counts were elevated upon diagnosis and these levels statistically significantly decreased after 6 months of treatment. Platelet activation was significantly increased after 6 months of treatment compared to levels at diagnosis (P-value < .05). Similarly, platelet apoptosis was also increased after 6 months of treatment. Abnormalities in platelet functioning found in this study may partly be due to clonal proliferation of haematopoietic cells in CML patients, specifically of megakaryocyte precursors as well as the inhibition of platelet tyrosine kinase's and the inhibition of platelet-derived growth factor. | en_ZA |
dc.description.department | Haematology | en_ZA |
dc.description.department | Internal Medicine | en_ZA |
dc.description.department | Physiology | en_ZA |
dc.description.librarian | hj2022 | en_ZA |
dc.description.sponsorship | Cancer Association of South Africa; Medical Research Council of South Africa; National Research Foundation; School of Medicine Research Committee of the Faculty of Health Sciences, University of Pretoria; Struwig-Germeshuysen Research Trust. | en_ZA |
dc.description.uri | http://wileyonlinelibrary.com/journal/cbf | en_ZA |
dc.identifier.citation | Repsold, L., Pool, R., Karodia, M., Tintinger, G., Becker, P. & Joubert, A.M. Apoptotic profiling of chronic myeloid leukaemia patients' platelets ex vivo before and after treatment with Imatinib. Cell Biochemistry and Function 2021; 39:562–570. https://doi.org/10.1002/cbf.3625. | en_ZA |
dc.identifier.issn | 0263-6484 (print) | |
dc.identifier.issn | 1099-0844 (online) | |
dc.identifier.other | 10.1002/cbf.3625 | |
dc.identifier.uri | http://hdl.handle.net/2263/84692 | |
dc.language.iso | en | en_ZA |
dc.publisher | Wiley | en_ZA |
dc.rights | © 2021 John Wiley and Sons, Ltd. This is the pre-peer reviewed version of the following article : Apoptotic profiling of chronic myeloid leukaemia patients' platelets ex vivo before and after treatment with Imatinib. Cell Biochemistry and Function 2021; 39:562–570. https://doi.org/10.1002/cbf.3625. The definite version is available at : http://wileyonlinelibrary.com/journal/cbf. | en_ZA |
dc.subject | Chronic myeloid leukaemia (CML) | en_ZA |
dc.subject | Platelets | en_ZA |
dc.subject | Imatinib | en_ZA |
dc.subject | Ex vivo | en_ZA |
dc.subject | Apoptosis | en_ZA |
dc.title | Apoptotic profiling of chronic myeloid leukaemia patients' platelets ex vivo before and after treatment with Imatinib | en_ZA |
dc.type | Postprint Article | en_ZA |